

CLAIMS

1. A solution comprising a multimeric biguanide compound in an amount ranging from about 0.00005 to about 0.0005% w/v, a quaternary ammonium compound in an amount ranging from about 0.00005 to about 0.0025 % w/v, an antifungal/anti-acanthamoeba agent in an amount ranging from about 0.00005 to about 0.0025% w/v and hyaluronic acid or a salt thereof in an amount ranging from about 0.015 to about 0.1% w/v.
2. The solution of claim 1, wherein the antifungal/anti-acanthamoeba agent is an amido-amine compound.
3. The solution of claim 2, wherein the multimeric biguanide compound is present in an amount ranging from about 0.0001 to about 0.0002% w/v, the quaternary ammonium compound is present in an amount ranging from about 0.000075 to about 0.001 % w/v and the amido-amine compound is present in an amount ranging from about 0.0001 to about 0.0018% w/v.
4. The solution of claim 2, wherein the multimeric biguanide compound is present in an amount ranging from about 0.00012 to about 0.00016% w/v, the quaternary ammonium compound is present in an amount ranging from about 0.000085 to about 0.00012 % w/v and the amido-amine compound is present in an amount ranging from about 0.0006 to about 0.0014% w/v.
5. The solution of any one of claims 1-4, wherein the hyaluronic acid or a salt thereof is present in an amount ranging from about 0.025 % w/v to about 0.085 % w/v.
6. The solution of any of claims 1-4, wherein the hyaluronic acid or a salt thereof is present in an amount ranging from about 0.04 % w/v to about 0.08 % w/v.
7. The solution of any one of claims 1-6, wherein the multimeric biguanide compound is selected from the group consisting of polyhexamethylene biguanide, polyaminopropyl biguanide and 1,1'-hexamethylene-bis(5-[2-ethylhexyl]biguanide), the quaternary ammonium compound is selected from the group consisting of Polyquaternium-1, Polyquaternium-10, Polyquaternium-42, N-dodecyl{4,4'-(2,4,8,10-tetraoxaspiro [5.5]undecan-3,9-diyl)}dipyridinium dibromide, 3,3'-[1,4-phenylenebis(oxy)]bis(1-dodecyl pyridinium)dibromide; 3-(3-hydroxy-2-(hydroxymethyl)-2-[(1-dodecylpyridinium-3-yl)oxy] methyl)propoxy)-1-dodecylpyridinium dibromide, 5,50-[2,20-(tetramethylenedicarbonyldioxy) diethyl]bis(3-alkyl-4-methylthiazolium iodide) and [4,40-(1,6-hexamethylenedithio)bis(1-octylpyridiniumiodide)], and the amido-amine compound is myristamidopropyl dimethylamine.

8. The solution of claim 7, wherein the multimeric biguanide compound is poly(hexamethylene biguanide) and the quaternary ammonium compound is Polyquaternium-1.
9. The solution of any one of claims 1-8 further comprising one or more of a chelating agent in an amount ranging from about 0.01 % w/v to about 0.06% w/v, and/or a buffer in an amount ranging from about 0.01 % w/v to about 1 % w/v, and/or a viscosity-modifying agent in an amount ranging from about 0.01 % w/v to about 0.25% w/v, and/or a surface-active compound in an amount ranging from about 0.01 % w/v to about 1 % w/v, and/or a tonicity agent in an amount ranging from about 0.001 % w/v to about 1 % w/v, and/or optionally a calcium salt in an amount ranging from about 0.001 % w/v to about 0.015% w/v and/or optionally a magnesium salt in an amount ranging from about 0.001 % w/v to about 0.015% w/v.
10. The solution of claim 9, wherein the chelating agent is ethylenediaminetetraacetic acid.
11. The solution of claim 9, wherein the buffer is a borate buffer or a phosphate buffer.
12. The solution of claim 9, wherein the viscosity-modifying agent is selected from the group consisting of hydroxypropylmethyl cellulose, carboxymethyl cellulose and hydroxyethyl cellulose.
13. The solution of claim 12, wherein the viscosity-modifying agent is hydroxypropylmethyl cellulose.
14. The solution of claim 9, wherein the surface-active compound is a poloxamine.
15. The solution of claim 9, wherein the tonicity agent is sodium chloride or a combination of sodium chloride and potassium chloride.
16. The solution of any one of claims 1 to 15, wherein the solution is a multipurpose disinfection solution.
17. The solution of any one of claims 1 to 16 for use in therapy.
18. The solution of any one of claims 1 to 16 for use in disinfection, in particular in ophthalmic application.
19. Non-therapeutic use of the solution of any one of claims 1 to 16 in disinfection, in particular of contact lenses.